Literature DB >> 25802344

Diagnosis of viral infections using myxovirus resistance protein A (MxA).

Ilka Engelmann1, François Dubos1, Pierre-Emmanuel Lobert1, Claire Houssin2, Vanessa Degas2, Anne Sardet3, Anne Decoster4, Anny Dewilde1, Alain Martinot2, Didier Hober5.   

Abstract

BACKGROUND: Myxoma resistance protein 1 (MxA) is induced during viral infections. MxA testing could be helpful to differentiate between viral and bacterial infections.
METHODS: A prospective multicenter cohort study was performed in pediatric emergency departments. MxA blood values were measured in children with confirmed viral or bacterial infections, uninfected controls, and infections of unknown origin. First patients were used to determine MxA threshold for viral infection. The diagnostic performance of MxA was determined by using receiver operating characteristic (ROC) analysis. Sensitivities (Se), specificities (Sp), and positive and negative likelihood ratios (LR+, LR-) were calculated.
RESULTS: The study included 553 children; 44 uninfected controls and 77 confirmed viral infections (mainly respiratory syncytial virus and rotavirus) were used to determine an MxA threshold at 200 ng/mL. In the 193 other patients with confirmed infections and uninfected controls (validation group), MxA was significantly higher in patients with viral than in those with bacterial infections and uninfected controls (P < .0001). The area under the ROC curve (AUC) were 0.98, with 96.4% Se and 85.4% Sp, for differentiating uninfected from virus-infected patients and 0.89, with 96.4% Se and 66.7% Sp, for differentiating bacterial and viral infections. MxA levels were significantly higher in patients with clinically diagnosed viral versus clinically diagnosed bacterial infections (P < .001). Some patients with Streptococcus pneumonia infections had high MxA levels. Additional studies are required to elucidate whether this was due to undiagnosed viral coinfections.
CONCLUSIONS: MxA is viral infection marker in children, at least with RSV and rotavirus. MxA could improve the management of children with signs of infection.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Keywords:  MxA; biomarker; children; myxoma resistance protein 1; virus

Mesh:

Substances:

Year:  2015        PMID: 25802344     DOI: 10.1542/peds.2014-1946

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  27 in total

1.  CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells.

Authors:  Ilaria Schiavoni; Carolina Scagnolari; Alberto L Horenstein; Pasqualina Leone; Alessandra Pierangeli; Fabio Malavasi; Clara M Ausiello; Giorgio Fedele
Journal:  Immunology       Date:  2017-12-18       Impact factor: 7.397

2.  Mapping theme trends and recognizing hot spots in viral pneumonia: a bibliometric analysis of global research.

Authors:  Lixue Wu; Hao Wu; Tianle Ou; Hao Huang; Liwei Duan; Wenfang Li; Weiwei Jiang
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

Review 3.  Biomarkers in Pediatric Community-Acquired Pneumonia.

Authors:  Nicola Principi; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2017-02-19       Impact factor: 5.923

4.  Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19.

Authors:  Tristan W Clark; Nathan J Brendish; Stephen Poole; Vasanth V Naidu; Christopher Mansbridge; Nicholas Norton; Helen Wheeler; Laura Presland; Sean Ewings
Journal:  J Infect       Date:  2020-06-21       Impact factor: 6.072

Review 5.  Future Biomarkers for Infection and Inflammation in Febrile Children.

Authors:  Judith Zandstra; Ilse Jongerius; Taco W Kuijpers
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

Review 6.  Virus-induced secondary bacterial infection: a concise review.

Authors:  Mohamed A Hendaus; Fatima A Jomha; Ahmed H Alhammadi
Journal:  Ther Clin Risk Manag       Date:  2015-08-24       Impact factor: 2.423

7.  Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection.

Authors:  Robert Sambursky; Nathan Shapiro
Journal:  Eur Clin Respir J       Date:  2015-12-10

8.  Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use.

Authors:  Patrick Joseph; Eliot Godofsky
Journal:  Open Forum Infect Dis       Date:  2018-02-15       Impact factor: 3.835

9.  Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections.

Authors:  Wesley H Self; Jeffrey Rosen; Stephan C Sharp; Michael R Filbin; Peter C Hou; Amisha D Parekh; Michael C Kurz; Nathan I Shapiro
Journal:  J Clin Med       Date:  2017-10-07       Impact factor: 4.241

Review 10.  Viral Sepsis in Children.

Authors:  Neha Gupta; Robert Richter; Stephen Robert; Michele Kong
Journal:  Front Pediatr       Date:  2018-09-18       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.